Regeneron Pharmaceuticals
Regeneron Pharmaceuticals has developed a drug that targets a pathway known as interleukin-6 or IL-6, which can affect inflammation. It's already approved for rheumatoid arthritis and could help very sick Covid-19 patients in respiratory distress.